GKOS

Glaukos Corp. (NYSE:GKOS)—an ophthalmic medical technology and pharmaceutical company—soared to a new all-time high on Thursday amid positive catalysts, including strong earnings, a higher growth outlook, and bullish analyst comments.

Glaukos came into the Q3 2026 print with a hot chart and a premium story, and the stock just got even hotter.

Glaukos’ two newer launches are carrying the company, and its 2027 target may be too low. Here’s what to watch.

Glaukos raises its full-year guidance, triggering a wave of price target hikes across Wall Street.

Key TakeawaysGlaukos shares jumped 26% today on record third-quarter sales and a $1 billion sales outlook for 2027. iDose TR and Epioxa made up about 61% of sales, so that target looks within reach.

Moby summary of Glaukos Corporation's Q3 2026 earnings call

Record sales and margin expansion driven by iDose TR and Epioxa launches.

Glaukos (NYSE:GKOS) reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment.

Glaukos (GKOS) delivered earnings and revenue surprises of +491.67% and +24.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.